New Ref-1/APE1 targeted inhibitors demonstrating improved potency for clinical applications in multiple cancer types.
Gampala S, Moon HR, Wireman R, Peil J, Kiran S, Mitchell DK, Brewster K, Mang H, Masters A, Bach C, Smith-Kinnamen W, Doud EH, Rai R, Mosley AL, Quinney SK, Clapp DW, Hamdouchi C, Wikel J, Zhang C, Han B, Georgiadis MM, Kelley MR, Fishel ML.
Gampala S, et al. Among authors: brewster k.
Pharmacol Res. 2024 Mar;201:107092. doi: 10.1016/j.phrs.2024.107092. Epub 2024 Feb 2.
Pharmacol Res. 2024.
PMID: 38311014
Free PMC article.